Vaccine Info

mRNA-1608 Herpes Vaccine

Authored by
Staff
Last reviewed
June 3, 2022
Fact checked by
Robert Carlson, MD
Share

mRNA-1608 Herpes Vaccine Candidate Description For 2022

Moderna's herpes simplex virus (HSV) vaccine candidate (mRNA-1608) is an mRNA vaccine targeted against HSV-2 disease. On February 18, 2022, Moderna Inc. stated that it expects an HSV-2 vaccine could provide cross-protection against HSV-1. With mRNA-1608, Moderna aims to induce a strong antibody response with neutralizing and effector functionality combined with cell-mediated immunity.

Moderna is developing mRNA-1608 to reduce the burden of HSV lesions. Moderna's mRNA vaccine technology offers potential advantages in efficacy, speed of development, and production scalability and reliability, which may position our company as a leader in preparing for and responding to infectious disease threats that place millions of people at risk worldwide.

To further characterize Moderna's IM vaccines, biodistribution studies were conducted to demonstrate where mRNA goes in the body after injection. Studies indicate that injected mRNA remains predominantly at the injection site and in nearby draining lymph nodes. Furthermore, consistent with its transient nature, mRNA is undetectable in the body five days after injection, with minimal mRNA detectable after only three days.

As of June 1, 2022, there is no herpes vaccine approved by the U.S. FDA; however, several herpes vaccine candidates are in development.

Massachusetts-based Moderna, Inc. (NASDAQ: MRNA) is a biotechnology company pioneering messenger RNA therapeutics and vaccines. Moderna now has vaccine candidates against latent viruses in development, including cytomegalovirus, Epstein-Barr virus, Human immunodeficiency virus, HSV, and VZV.

mRNA-1608 Indication

 In the U.S., approximately 18.6 million adults ages 18 to 49 years live with HSV-2. The U.S. CDC says herpes simplex viruses are categorized into two types: HSV-1 infects the mouth, face, and genitals, and HSV-2 primarily infects the genitals. Both herpes viruses establish lifelong latent infections within sensory neurons from which they can reactivate and re-infect the skin.

Moderna Inc. Financial News For 2022

May 4, 2022 - The Company announced first quarter 2022 revenues of $6.1 billion; GAAP net income of $3.7 billion, and GAAP diluted EPS of $8.58.

Feb. 24, 2022 - Moderna, Inc. reported full-year 2021 revenues of $18.5 billion; GAAP net-income of $12.2 billion and GAAP diluted EPS of $28.29.

mRNA-1608 Herpes Vaccine Candidate News

May 24, 2022 - Digital Journal reported: Here at Meet Positives, we are very grateful for the progress Moderna has made with its mRNA vaccine and can't wait for it to positively affect the lives of the millions of citizens living today under the fear of contracting herpes."

May 4, 2022 - Moderna confirmed preclinical studies are underway for the mRNA-1608 vaccine candidate.

March 24, 2022 - Moderna Inc. confirmed preclinical studies are underway for VZV (mRNA-1468) and HSV (mRNA-1608) vaccine candidates, both members of the Herpesviridae family that establish life-long latent infections.

February 18, 2022 - Moderna, Inc. announced an expansion of its mRNA vaccine pipeline with three new development programs. "We are pleased to announce these new development programs, which reflect the continued productivity of our platform and the potential of our mRNA technology to impact the lives of hundreds of millions of people," said Stéphane Bancel, Chief Executive Officer of Moderna. 

mRNA-1608 Herpes Vaccine Candidate Clinical Trials

Moderna publishes clinical trial updates at this weblink.

Clinical Trials

No clinical trials found